Target Price | GBP16.66 |
Price | GBP13.34 |
Potential |
24.90%
register free of charge
|
Number of Estimates | 17 |
17 Analysts have issued a price target GlaxoSmithKline 2025 .
The average GlaxoSmithKline target price is GBP16.66.
This is
24.90%
register free of charge
GBP24.80
85.91%
register free of charge
GBP11.90
10.79%
register free of charge
|
|
A rating was issued by 23 analysts: 9 Analysts recommend GlaxoSmithKline to buy, 10 to hold and 4 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the GlaxoSmithKline stock has an average upside potential 2025 of
24.90%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Billion GBP | 30.33 | 31.12 |
3.42% | 2.61% | |
EBITDA Margin | 30.62% | 33.24% |
1.71% | 8.55% | |
Net Margin | 16.41% | 11.79% |
68.20% | 28.16% |
17 Analysts have issued a sales forecast GlaxoSmithKline 2024 . The average GlaxoSmithKline sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an GlaxoSmithKline EBITDA forecast 2024. The average GlaxoSmithKline EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 GlaxoSmithKline Analysts have issued a net profit forecast 2024. The average GlaxoSmithKline net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share GBP | 1.22 | 0.90 |
67.12% | 26.23% | |
P/E | 14.93 | |
EV/Sales | 2.16 |
12 Analysts have issued a GlaxoSmithKline forecast for earnings per share. The average GlaxoSmithKline <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the GlaxoSmithKline stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
GlaxoSmithKline...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.